Literature DB >> 20094046

Fibroblast growth factor signalling: from development to cancer.

Nicholas Turner1, Richard Grose.   

Abstract

Fibroblast growth factors (FGFs) and their receptors control a wide range of biological functions, regulating cellular proliferation, survival, migration and differentiation. Although targeting FGF signalling as a cancer therapeutic target has lagged behind that of other receptor tyrosine kinases, there is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumour types, and clinical reagents that specifically target the FGFs or FGF receptors are being developed. Although FGF signalling can drive tumorigenesis, in different contexts FGF signalling can mediate tumour protective functions; the identification of the mechanisms that underlie these differential effects will be important to understand how FGF signalling can be most appropriately therapeutically targeted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20094046     DOI: 10.1038/nrc2780

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  187 in total

Review 1.  FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease.

Authors:  David M Ornitz; Pierre J Marie
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

2.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

3.  PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

Authors:  Elena López-Knowles; Silvia Hernández; Núria Malats; Manolis Kogevinas; Josep Lloreta; Alfredo Carrato; Adonina Tardón; Consol Serra; Francisco X Real
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  Male-to-female sex reversal in mice lacking fibroblast growth factor 9.

Authors:  J S Colvin; R P Green; J Schmahl; B Capel; D M Ornitz
Journal:  Cell       Date:  2001-03-23       Impact factor: 41.582

5.  FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Authors:  Adel H Jebar; Carolyn D Hurst; Darren C Tomlinson; Colin Johnston; Claire F Taylor; Margaret A Knowles
Journal:  Oncogene       Date:  2005-08-04       Impact factor: 9.867

6.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

7.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.

Authors:  S Xiao; S R Nalabolu; J C Aster; J Ma; L Abruzzo; E S Jaffe; R Stone; S M Weissman; T J Hudson; J A Fletcher
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

8.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.

Authors:  F Courjal; M Cuny; J Simony-Lafontaine; G Louason; P Speiser; R Zeillinger; C Rodriguez; C Theillet
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

9.  Stromal gene expression predicts clinical outcome in breast cancer.

Authors:  Greg Finak; Nicholas Bertos; Francois Pepin; Svetlana Sadekova; Margarita Souleimanova; Hong Zhao; Haiying Chen; Gulbeyaz Omeroglu; Sarkis Meterissian; Atilla Omeroglu; Michael Hallett; Morag Park
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

10.  An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis.

Authors:  L De Moerlooze; B Spencer-Dene; J M Revest; M Hajihosseini; I Rosewell; C Dickson
Journal:  Development       Date:  2000-02       Impact factor: 6.868

View more
  943 in total

1.  VEGF and VEGFR1 levels in different regions of the normal and preeclampsia placentae.

Authors:  Akriti S Sahay; Anjali T Jadhav; Deepali P Sundrani; Girija N Wagh; Savita S Mehendale; Preeti Chavan-Gautam; Sadhana R Joshi
Journal:  Mol Cell Biochem       Date:  2017-08-02       Impact factor: 3.396

2.  The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.

Authors:  Leo Y Luo; Eejung Kim; Hiu Wing Cheung; Barbara A Weir; Gavin P Dunn; Rhine R Shen; William C Hahn
Journal:  Mol Cancer Res       Date:  2014-11-03       Impact factor: 5.852

3.  Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats.

Authors:  Tsung-Jung Ho; Chi-Chang Huang; Chih-Yang Huang; Wan-Teng Lin
Journal:  Eur J Appl Physiol       Date:  2011-12-09       Impact factor: 3.078

4.  FGF-dependent regulation of VEGF receptor 2 expression in mice.

Authors:  Masahiro Murakami; Loc T Nguyen; Kunihiko Hatanaka; William Schachterle; Pei-Yu Chen; Zhen W Zhuang; Brian L Black; Michael Simons
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

5.  Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Authors:  Mingqiang Ren; Haiyan Qin; Ruizhe Ren; Josephine Tidwell; John K Cowell
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

6.  Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.

Authors:  Michael M Fisher; Gopika SenthilKumar; Rong Hu; Steve Goldstein; Irene M Ong; Margot C Miller; Sean R Brennan; Saakshi Kaushik; Lindsey Abel; Kwangok P Nickel; Gopal Iyer; Paul M Harari; Randall J Kimple; Andrew M Baschnagel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-13       Impact factor: 7.038

7.  Pten loss induces autocrine FGF signaling to promote skin tumorigenesis.

Authors:  Kristina Hertzler-Schaefer; Grinu Mathew; Ally-Khan Somani; Sunil Tholpady; Madhavi P Kadakia; Yiping Chen; Dan F Spandau; Xin Zhang
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

8.  Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial.

Authors:  Yihebali Chi; Guangqian Ji; Jing Zhang; Haijian Tang; Yang Yang; Wei Liu; Nan Wang; Chunhui Gao; Yongkun Sun; Jinwan Wang
Journal:  Int J Clin Oncol       Date:  2021-07-23       Impact factor: 3.402

9.  Characterization and Quantification of Highly Sulfated Glycosaminoglycan Isomers by Gated-Trapped Ion Mobility Spectrometry Negative Electron Transfer Dissociation MS/MS.

Authors:  Juan Wei; Jiandong Wu; Yang Tang; Mark E Ridgeway; Melvin A Park; Catherine E Costello; Joseph Zaia; Cheng Lin
Journal:  Anal Chem       Date:  2019-01-31       Impact factor: 6.986

10.  FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Authors:  Murry W Wynes; Trista K Hinz; Dexiang Gao; Michael Martini; Lindsay A Marek; Kathryn E Ware; Michael G Edwards; Diana Böhm; Sven Perner; Barbara A Helfrich; Rafal Dziadziuszko; Jacek Jassem; Szymon Wojtylak; Aleksandra Sejda; Joseph M Gozgit; Paul A Bunn; D Ross Camidge; Aik-Choon Tan; Fred R Hirsch; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.